Global Cephalosporin Drugs Market 2015-2019 - Use of Combination Therapies

News provided by

Oct 28, 2015, 12:10 ET

DUBLIN, Oct. 28, 2015 /PRNewswire/ --

Research and Markets(http://www.researchandmarkets.com/research/xgxhhr/global) has announced the addition of the "Global Cephalosporin Drugs Market 2015-2019" report to their offering.

The global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019

The report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.

The increased approvals and use of combination drugs is an emerging trend in the global cephalosporin drugs market. Combination therapies are found to show better efficacy than monotherapies. Also, the use of monotherapies leads to easy development of resistance. This can be avoided by the judicious use of combination drugs.

According to the report, the increased awareness of diseases and their treatment options helps detect and treat infections during their early stages. The European Antibiotic Awareness Day is celebrated on November 18 every year to raise awareness about antibiotic resistance and promote the judicious use of antibiotics. Such programs about the disease and treatment options increase the treatment-seeking population, driving the growth of the market.

Further, the report states that most drugs in the cephalosporin market are generics, resulting in decreased revenue for the products. Some drugs that have expired and have a generic form as of today include cefuroxime axetil, ceftazidime, and cefprozil.

Key vendors

Allergan
Astellas
Bristol-Myers Squibb
GlaxoSmithKline
Merck
Pfizer
Sandoz
Teva Pharmaceuticals

Other prominent vendors

Abbott
Aspen Pharmacare
AstraZeneca
Aurobindo Pharma
Basilea Pharmaceuticals
Baxter
Biocon
Corden Pharma
Cornerstone Therapeutics
Eli Lilly
F. Hoffmann-La Roche
Flynn Pharma
Hospira
Incepta Pharmaceuticals
Johnson & Johnson
Kyorin Pharmaceutical
Lupin Pharmaceuticals
Orchid Pharma
Par Pharmaceutical
Pernix Therapeutics
Sanofi
Shionogi
Sun Pharmaceutical
Takeda Pharma
Theravance Biopharma
Wockhardt

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Cephalosporin overview

Part 06: Overview on the consumption of antibiotics

Part 07: Legislation relating to antibiotic use in the US

Part 08: Market landscape

Part 09: Market segmentation by generation of cephalosporin

Part 10: Market segmentation by route of administration

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

For more information visit http://www.researchandmarkets.com/research/xgxhhr/global